Intravitreal faricimab resulted in favorable anatomical and functional recovery for two patients presenting with persistent cystoid macular edema secondary to uveitis-glaucoma-hyphema syndrome, according to clinical findings published in the Journal of Ophthalmic Inflammation and Infection. The peer-reviewed report documents the successful resolution of fluid accumulation alongside measurable improvements in visual acuity following administration of the medication.
The initial protocols incorporated topical nonsteroidal anti-inflammatory drugs, topical corticosteroids, and targeted periocular corticosteroid injections. Despite these multiple interventions, neither patient achieved anatomical resolution of the cystoid macular edema, which remained persistent.
To avoid the risks associated with corticosteroid-induced ocular hypertension, each patient subsequently received a single intravitreal injection of faricimab. Following the procedure, both individuals experienced complete anatomical resolution of their cystoid macular edema, coupled with documented improvements in visual acuity and sustained anatomical stability throughout post-treatment follow-up examinations.
In their published conclusion, lead author Georgios Batsos and the research team highlighted that intravitreal faricimab demonstrated positive functional and anatomical outcomes in both refractory cases. The authors suggested that faricimab represents a viable alternative treatment strategy for persistent macular edema in selected patients whose therapeutic options are constrained by coexisting ocular disease.
Subject of Research: Intravitreal faricimab treatment for persistent cystoid macular edema secondary to uveitis-glaucoma-hyphema syndrome
Article Title: Intravitreal faricimab for refractory macular edema associated with uveitis-glaucoma-hyphema syndrome: a report of two cases
Article References: Batsos, G., Kontomichos, L., Karagiannis, D., Christou, E. E., Christodoulou, E., Bouratzis, N., & Paroikakis, E. (2026). Intravitreal faricimab for refractory macular edema associated with uveitis-glaucoma-hyphema syndrome: a report of two cases. Journal of Ophthalmic Inflammation and Infection. https://doi.org/10.1186/s12348-026-00633-7
Image Credits: AI Generated
DOI: 10.1186/s12348-026-00633-7
Keywords: faricimab, intravitreal injection, macular edema, cystoid macular edema, uveitis-glaucoma-hyphema syndrome, UGH syndrome, intraocular lens, sulcus implantation, iris chafing, glaucoma, intraocular pressure, visual acuity, ophthalmology, retina, corticosteroids, case report
News Source: Ophelia Keating. (November 19, 2026). Faricimab Resolves Refractory Macular Edema in Two UGH Syndrome Cases. Scienmag.



